Editorial Board

Back to Top
Our editorial board is comprised of cancer experts, organized primarily by disease focus. If you are interested in getting involved, please feel free to contact us with any questions or inquiries, at contact @ hemonc.org.
=Editor-in-Chief=
	Peter C. Yang, MDBoston, MA, USA	Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts.
=Deputy Editor=
	Andrew J. Cowan, MDSeattle, WA, USALinkedIn	Dr. Cowan is board certified in Hematology and Medical Oncology; he is the Research Director of the myeloma service at the Fred Hutch Cancer Center. He is an associate professor at the University of Washington.
=Associate Editors=
Cancer Registries 	Cancer Registries 	Cancer Registries
 	Mary Mesnard, BS, CTRLinkedIn 	Ms. Mesnard is a certified oncology data specialist with 36 years of experience working in hospital and more recently, central cancer registries. Her primary focus is managing central registries and quality assurance.
Evidence-based Oncology 	Evidence-based Oncology 	Evidence-based Oncology
 	Martin W. Schoen, MD, MPHSaint Louis UniversitySt. Louis, MO, USA 	Dr. Schoen is board certified in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University.
Pediatric Hematology/Oncology	Pediatric Hematology/Oncology 	Pediatric Hematology/Oncology
 	Nicole M. Wood, DOUniversity of MissouriKansas City, MO, USALinkedIn 	Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics at the University of Missouri.
Radiation Oncology 	Radiation Oncology 	Radiation Oncology
 	Danielle S. Bitterman, MDDana-Farber Cancer InstituteBoston, MA, USALinkedIn	Dr. Bitterman is board certified in Radiation Oncology; she practices at Brigham and Women’s Hospital/Dana-Farber Cancer Institute. She is an Assistant Professor of Radiation Oncology at Harvard Medical School.
Supportive Oncology 	Supportive Oncology 	Supportive Oncology
 	Maryam B. Lustberg, MD, MPHYale UniversityNew Haven, CT, USALinkedIn 	Dr. Lustberg is board certified in Medicine and Medical Oncology; she is the director of the Breast Center at Smilow Cancer Hospital and chief of Breast Medical Oncology at Yale Cancer Center. She is an Associate Professor of Internal Medicine (Medical Oncology) at Yale University. She is the co-chair of Symptom Intervention Committee for Alliance Clinical Trials, and the 2022 president of the Multinational Association of Cancer Supportive Care (MASCC)
=Regional Associate Editors=
Asia 	Asia 	Asia
 	Unfilled 	If you are interested in this role, please contact us at contact @ hemonc.org.
Europe and United Kingdom 	Europe and United Kingdom 	Europe and United Kingdom
 	Mark P. Lythgoe, MBBS, PharmDImperial College LondonLondon, England, UKLinkedIn 	Dr. Lythgoe is a medical oncologist, clinical pharmacist, and health services researcher. His work involves analyzing cancer drug approvals and regulatory pathways.
Middle East and North Africa	Middle East and North Africa 	Middle East and North Africa
 	Unfilled 	If you are interested in this role, please contact us at contact @ hemonc.org.
Oceania 	Oceania 	Oceania
 	Georgina Kennedy, PhDIngham Institute for Applied Medical ResearchSydney, NSW, AustraliaLinkedIn 	Dr. Kennedy is a health data infrastructure specialist and data engineer. Her work involves harmonizing systemic anticancer therapy standards, including the eviQ resource of evidence-based, consensus driven cancer treatment protocols.
 	Salvatore (Sam) Fiorenza, MBBS, PhD, BSc(Hons), MPH, FRACP, FRCPAUniversity of SydneyCamperdown, NSW, AustraliaLinkedIn	Dr. Fiorenza is a haematologist and physician-scientist with an interest in treating malignant haematological conditions, especially acute myeloid leukemia and stem cell transplantation. Sam conducts research immunotherapy with a particular interest in CAR T-cell therapy. Sam is also the deputy director and medical lead of cellular therapy at Epworth HealthCare.
Latin America 	Latin America 	Latin America
 	Unfilled 	If you are interested in this role, please contact us at contact @ hemonc.org.
Sub-Saharan Africa 	Sub-Saharan Africa 	Sub-Saharan Africa
 	Clement Dove Okello, MMed, MBChBUganda Cancer InstituteKampala, UgandaLinkedIn 	Clement Dove Okello is a consultant Clinical Haematologist at the Uganda Cancer Institute. He graduated with a Bachelor’s of Medicine and Bachelor’s of Surgery degree and a Master’s of Medicine degree in Internal Medicine from Makerere University, Uganda in 2007 and 2014 respectively. He also completed a Fellowship training in Clinical Haematology from McMaster University, Canada in 2016. Clement is passionate about improving patient care, clinical research and training of health care personnel in sub-Saharan Africa. Beyond his profession, he enjoys singing in a choir, gardening and nature walks.
=Section Editors=
Breast Oncology 	Breast Oncology 	Breast Oncology
 	Gayathri Nagaraj, MDLoma Linda, CA, USALinkedIn 	Dr. Nagaraj is board certified in Hematology and Medical Oncology. She is an Associate Professor of Medicine at Loma Linda University and the Program Director of the Hematology and Medical Oncology fellowship program at Loma Linda University Health Education Consortium (LLUHEC). Her clinical practice focuses on breast cancer.
Dermatologic Oncology 	Dermatologic Oncology 	Dermatologic Oncology
 	Elizabeth Buchbinder, MDBoston, MA, USALinkedIn 	Dr. Buchbinder is board certified in Medical Oncology; she is a senior physician at the Dana-Farber Cancer Institute. She is an Assistant Professor of Medicine at Harvard Medical School.
Endocrine Oncology 	Endocrine Oncology 	Endocrine Oncology
 	Unfilled 	If you are interested in this role, please contact us at contact @ hemonc.org.
Gastrointestinal Oncology, Intestinal 	Gastrointestinal Oncology, Intestinal 	Gastrointestinal Oncology, Intestinal
 	Travis Zack MD, PhDSan Francisco, CA, USA 	Dr. Zack is board certified in Internal Medicine and board eligible for Medical Oncology. He is an Assistant Professor of Medicine at the University of California, San Francisco.
Gastrointestinal Oncology, Extraintestinal 	Gastrointestinal Oncology, Extraintestinal 	Gastrointestinal Oncology, Extraintestinal
 	Eric I. Marks, MDBoston, MA, USA 	Dr. Marks is board certified in Medical Oncology; he practices at Boston Medical Center and is an Assistant Professor of Medicine at Boston University School of Medicine.
Genitourinary Oncology 	Genitourinary Oncology 	Genitourinary Oncology
 	Ali Raza Khaki, MDPalo Alto, CA, USA 	Dr. Khaki is a Clinical Assistant Professor of Medicine/Oncology at Stanford University School of Medicine and genitourinary medical oncology at Stanford Cancer Center. He is board certified in Hematology and Medical Oncology.
Gynecologic Oncology 	Gynecologic Oncology 	Gynecologic Oncology
 	Alaina J. Brown, MD, MPHNashville, TN, USA 	Dr. Brown is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at the Vanderbilt-Ingram Cancer Center. She is an Associate Professor of Obstetrics and Gynecology at Vanderbilt University.
e'Head & Neck Cancer' 	e'Head & Neck Cancer' 	e'Head & Neck Cancer'
iat 	Aditya Shreenivas, MD, MSDuarte, CA, USA 	Dr. Shreenivas is an Assistant Professor in the Department of Gastrointestinal and Head & Neck Medical Oncology at the City of Hope Comprehensive Cancer Center – Duarte Campus. Dr. Shreenivas is board certified in Internal Medicine, Hematology, and Medical Oncology.
Mesothelioma 	Mesothelioma 	Mesothelioma
 	Marjorie G. Zauderer, MD, MS, FACPNew York, NY, USA 	Marjorie G. Zauderer, MD, MS, FACP is Section Chief, Hematology and Medical Oncology at the Westchester Medical Center. She received her medical degree from Columbia University's College of Physicians and Surgeons, completed her residency in Internal Medicine at the New York-Presbyterian Hospital Columbia University Medical Center, and completed fellowship and chief fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Dr. Zauderer cares for patients with mesothelioma and other thoracic malignancies. Her practice aims to provide personalized care to patients throughout the course of their treatment based not only on the type of cancer and its genetics but the individual priorities of each and every patient and family. She is also an active translational and clinical researcher and focuses on the development of new therapies for the treatment of mesothelioma and lung cancers. She has received several federally funded grants for her research including a Department of Defense (DOD) Career Development Award, DOD Translational Team Science Award, and 2 R01s. She reviews grants for foundations as well as the Department of Defense and National Cancer Institute. Dr. Zauderer has lectured and presented her work throughout the United States and international thoracic community and has authored/co-authored more than 80 peer-reviewed oncology manuscripts. Dr. Zauderer is board certified in Medical Oncology.
Neuro-Oncology 	Neuro-Oncology 	Neuro-Oncology
 	Seema Nagpal, MDPalo Alto, CA, USA 	Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a Clinical Professor of Neurology at Stanford University
Sarcoma 	Sarcoma 	Sarcoma
 	Elizabeth J. Davis, MDNashville, TN, USA 	Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center and is the medical director of the Clinical Trials Office. She is an associate professor at Vanderbilt University.
Thoracic Oncology 	Thoracic Oncology 	Thoracic Oncology
 	Amit Kulkarni, MBBSUniversity of MinnesotaMinneapolis, MN, USA 	Dr. Kulkarni is board certified in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota.
Acute Leukemias 	Acute Leukemias 	Acute Leukemias
frameless|upright=0.4|center 	Ashwin Kishtagari, MDVanderbilt UniversityNashville, TN, USA 	Dr. Kishtagari practices at Vanderbilt University Medical Center. He is an Assistant Professor of Medicine (Hematology/Oncology) at Vanderbilt University. He is board-certified in Internal Medicine and Medical Oncology.
Myeloproliferative Neoplasms and Myelodysplastic Syndromes	Myeloproliferative Neoplasms and Myelodysplastic Syndromes 	Myeloproliferative Neoplasms and Myelodysplastic Syndromes
 	Sanjay R. Mohan, MD, MSCINashville, TN, USA 	Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University.
Aggressive Lymphomas & Lymphoproliferative disorders 	Aggressive Lymphomas & Lymphoproliferative disorders 	Aggressive Lymphomas & Lymphoproliferative disorders
 	Tarsheen K. Sethi, MD, MSCIYale UniversityNew Haven, CT, USA 	Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University.
Indolent Lymphomas 	Indolent Lymphomas 	Indolent Lymphomas
 	Sanjai Sharma, MDVisalia, CA, USA 	Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center.
Plasma Cell Dyscrasias 	Plasma Cell Dyscrasias 	Plasma Cell Dyscrasias
 	Samuel M. Rubinstein, MDUniversity of North CarolinaChapel Hill, NC, USALinkedIn	Dr. Rubinstein is board certified in Hematology and Medical Oncology; he is a clinical assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias.
T-cell and NK-cell neoplasms 	T-cell and NK-cell neoplasms 	T-cell and NK-cell neoplasms
 	Bhagirathbhai Dholaria, MBBSNashville, TN, USA 	Dr. Dholaria is currently an associate professor in the Department of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, TN. His areas of specialization and primary research focus are lymphoid neoplasms, plasma cell malignancies, adoptive cellular therapies, and stem cell transplantation. He has conducted studies investigating the outcomes of patients with non- Hodgkin lymphoma and acute leukemia undergoing chimeric antigen receptor T-cell (CAR-T) therapies. He is involved in translational research investigating the biomarkers of CAR T-cell therapy-associated toxicities. He has also conducted several observational studies utilizing cancer registries to study transplant outcomes of acute leukemia patients and presented his findings in national meetings. His team's work on stem cell transplantation has been published in multiple manuscripts. His current research efforts are focused on testing novel agents to address relapse after CAR T therapy in lymphoma and multiple myeloma. Dr. Dholaria is board certified in Hematology and Medical Oncology.
Histiocytic Disorders 	Histiocytic Disorders 	Histiocytic Disorders
 	Gaurav Goyal, MBBSUABBirmingham, AL, USA 	Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at the O'Neal Comprehensive Cancer Center at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham).
Pediatric Blastomas & Extracranial Germ Cell Tumors 	Pediatric Blastomas & Extracranial Germ Cell Tumors 	Pediatric Blastomas & Extracranial Germ Cell Tumors
 	Elaine M. Fan, MD, MSWichita, KS, USA 	Dr. Fan is a Clinical Assistant Professor of Pediatrics at the University of Kansas and practices at Wesley Medical Center. She is particularly interested in applying clinical informatics to improve clinical workflow efficiency, enhance provider and patient experience and, ultimately, improve health outcomes in pediatrics and pediatric hematology-oncology. Dr. Fan is board-certified in Pediatrics and Clinical Informatics, and board-eligible in Pediatric Hematology-Oncology.
Pediatric Leukemia & Lymphoma 	Pediatric Leukemia & Lymphoma 	Pediatric Leukemia & Lymphoma
 	David Noyd, MD, MPHUniversity of WashingtonSeattle, WA, USA 	Dr. Noyd is board certified in Pediatrics and board eligible in Pediatric Hematology-Oncology; he practices at Seattle Children's Hospital. He is an Assistant Professor of Pediatrics at the University of Washington.
Pediatric Neuro-Oncology & Solid Tumors 	Pediatric Neuro-Oncology & Solid Tumors 	Pediatric Neuro-Oncology & Solid Tumors
 	Unfilled 	If you are interested in this role, please contact us at contact @ hemonc.org.
Transplant 	Transplant 	Transplant
 	Talal Hilal, MDMayo ClinicPhoenix, AZ, USA 	Dr. Hilal is a hematologist/oncologist and bone marrow transplant physician with a clinical focus on chronic lymphocytic leukemia, lymphoid malignancies, and rare histiocytic neoplasms. Dr. Hilal attended medical school at the Royal College of Surgeons in Ireland. He obtained training in internal medicine at the University of Kentucky and in hematology/oncology at the Mayo Clinic in Phoenix, Arizona where he served as Chief Fellow. Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at Mayo Clinic Arizona. He is an assistant professor at the Mayo Clinic.
Classical Hematology 	Classical Hematology 	Classical Hematology
 	Benjamin Tillman, MDVanderbilt UniversityNashville, TN, USA 	Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an Assistant Professor of Medicine (Hematology/Oncology)
Guidelines 	Guidelines 	Guidelines
 	Sandeep K. Jain, MDBrown UniversityProvidence, RI, USA 	Dr. Jain is a senior hematology/oncology fellow at Brown University; he is board certified in Internal Medicine.
Living Systematic Reviews 	Living Systematic Reviews 	Living Systematic Reviews
 	Irbaz Bin Riaz, MD, PhD, MSMayo ClinicPhoenix, AZ, USA 	Dr. Riaz is board certified in Internal Medicine and Medical Oncology; he is an Assistant Professor of Medicine at Mayo Clinic, Arizona.
=Pharmacy Editors=
Clinical Pharmacology 	Clinical Pharmacology 	Clinical Pharmacology
 	Grace Baek, PharmD, BCOPUW Medicine / Fred Hutchinson Cancer CenterSeattle, WA, USALinkedIn 	Dr. Baek is a Clinical Oncology Pharmacist at the Fred Hutchinson Cancer Center. She is Board Certified in Oncology Pharmacy.
 	Nicholas Bitz, PharmD, MBA, MSPGxUniversity Hospitals Cleveland Medical CenterCleveland, OH, USALinkedIn	Dr. Bitz graduated with a PharmD from South Dakota State University in 2015, and entered community pharmacy practice for two years before starting as a clinical pharmacist with University Hospitals in Cleveland, OH in 2017. He began working in outpatient oncology infusion in 2018 and worked in that space for 5 years, before beginning a role as a oncology clinical specialist at University Hospitals Seidman Cancer Center in 2023, specializing in multiple myeloma and lymphoma. He earned an MBA from Dakota State University in 2022 and earned as Masters in Pharmacogenomics from Manchester University in 2024.
 	Sotirios Diamantoudis, MPharmcAristotle UniversityThessaloniki, GreeceLinkedIn 	Mr. Diamantoudis is currently a Pharmacy student at the Aristotle University of Thessaloniki, Greece. Interested in the fields of biopharmaceuticals, oncology, immunotherapies and cell and gene therapies.
 	Rachel Feaster, PharmD, BCOP, BCPSFred Hutchinson Cancer CenterSeattle, WA, USALinkedIn 	Rachel Feaster is a board certified clinical oncology pharmacist with a specialized focus in community oncology care and integrative medicine. Rachel received her Doctor of Pharmacy degree from the University of Missouri-Kansas City and completed her PGY1 residency at the Veterans Affairs Puget Sound Health Care System in Seattle, WA. Rachel is also board certified in pharmacotherapy and has a diverse background including 10+ years of professional experience in ambulatory, inpatient, pharmacogenomics, and oncology care. She currently practices as a clinical oncology pharmacist at Fred Hutchinson Cancer Center in Seattle, WA.
 	Austin Fitts, PharmDNational Cancer InstituteSilver Springs, MD, USALinkedIn 	Dr. Fitts is a Postdoctoral Fellow at the National Cancer Institute.
 	Laura Roccograndi, PharmD, BCOPFred Hutchinson Cancer CenterSeattle, WA, USALinkedIn 	Dr. Roccograndi is a clinical pharmacy specialist at the Fred Hutchinson Cancer Center. She is Board Certified in Oncology Pharmacy.
 	Emily Waite, PharmD, BCOPChildren's of AlabamaBirmingham, AL, USALinkedIn 	Emily S. Waite, Pharm.D., BCOP, is a Pediatric Hematology/Oncology Pharmacist with the Alabama Center for Childhood Cancer and Blood Disorders at Children's of Alabama in Birmingham. Emily grew up in Ooltewah, Tennessee, moving to Birmingham to complete here undergraduate degree at the UAB. After earning her Bachelor of Science degree in biology from UAB, Dr. Waite earned her Doctor of Pharmacy degree from Auburn University Harrison School of Pharmacy. She completed a PGY1 Pharmacy Practice Residency at Children's of Alabama. For the past 14 years, Emily has provided inpatient and outpatient care for the Hematology/Oncology Division at Children's of Alabama. Emily now works as a Beacon and Willow Analyst for the informatics department, while continuing to serve as a clinical resource for the Center for Childhood Cancer and Blood Disorders at Children's of Alabama in Birmingham. She is Board Certified in Oncology Pharmacy.
frameless|upright=0.4|center	Bradley Yelvington, PharmD, BCOPVanderbilt University Medical CenterNashville, TN, USALinkedIn 	Dr. Yelvington is a Board-Certified Oncology Pharmacist practicing since 2017 at Vanderbilt University Medical Center in Adult Malignant Hematology. He is Board Certified in Oncology Pharmacy.
 	Carolnn Yong, PharmD, BCPS, BCOPProvidence Holy Cross Medical CenterMission Hills, CA, USALinkedIn 	Dr. Yong is a Board Certified Oncology Pharmacist.
=Page Editors=
*Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA, USA)
**Chronic lymphocytic leukemia
*Brianna Bakow, MD (Brigham and Women's Hospital, Boston, MA, USA)
**Antiphospholipid antibody syndrome
*Joshua Brandstadter, MD, PhD, MSc (University of Pennsylvania, Philadelphia, PA, USA)
**Castleman disease
*Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY, USA)
**Renal cell carcinoma
***Clear cell renal cell carcinoma
***Non-clear cell renal cell carcinoma
****Papillary renal cell carcinoma
****Sarcomatoid renal cell carcinoma
***RCC, VHL-associated
*Michael J. Glover, MD (Stanford University, Palo Alto, CA, USA)
**Urothelial carcinoma
***Bladder cancer
**Testicular cancer
*Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO, USA)
**Prostate cancer
*Matthew Hadfield, DO (Brown University, Providence, RI, USA)
**Immunotherapy toxicity management
*Shalin Kothari, MD (Yale University, New Haven, CT, USA)
**Mantle cell lymphoma
*Mary L. Kwok, MD, FACP (Fred Hutchinson Cancer Center, Seattle, WA, USA)
**Multiple myeloma, relapsed-refractory
*Emily A. Mann, MD (Boston University, Boston, MA, USA)
**Gallbladder cancer
*Eric I. Marks, MD (Boston University, Boston, MA, USA)
**Gastrointestinal stromal tumor
*Francesca Montanari, MD (Yale University, New Haven, CT, USA)
**Post-transplant lymphoproliferative disorder
*Ryan H. Nguyen, DO (University of Illinois at Chicago, IL, USA)
**Melanoma
*Michael K. Rooney, MD (MD Anderson Cancer Center, Houston, TX, USA)
**Radiotherapy toxicity management
*Eric K. Singhi, MD (MD Anderson Cancer Center, Houston, TX, USA)
**Non-small cell lung cancer
*Leyre Zubiri, MD, PhD (Massachusetts General Hospital, Boston, MA, USA)
**Immunotherapy toxicity management
=COI Disclosures=
Please see our conflict of interest page for more details. Disclosures here are for COI within 24 months of the date of disclosure unless otherwise noted.
Name 	Research funding (to institution) 	Other (honoraria, travel support, significant ownership interests, etc.) 	Date of disclosure
Jon Arnason 	Nothing to disclose 	Speaker: Bristol-Myers Squibb & RegeneronTravel support: Regeneron 	2024-08-19
Grace Baek 	Nothing to disclose 	Education: Postgraduate Healthcare, LLC (funding from Bristol-Myers Squibb) 	2024-10-17
Brianna Bakow 	Nothing to disclose 	Nothing to disclose 	2023-08-27
Danielle S. Bitterman 	Research funding from ACS, ASTRO, and the NIH 	Scientific Advisory Board: MercurialAI 	2024-08-21
Joshua Brandstadter 	Nothing to disclose 	Consulting: Recordati Rare Disease 	2024-07-17
Alaina J. Brown 	NIH 	Nothing to disclose 	2024-08-02
Elizabeth Buchbinder 	NIH; Clinical trial support from Lilly, Novartis, Partners therapeutics, Genentech and BVD. 	Consultant/advisory board member for Pfizer, Werewolf pharma, Merck, Iovance, Sanofi, Xilio, Anaveon, Obsidian and Novartis. 	2024-12-02
Andrew Cowan 	Janssen, BMS, Juno/Celgene, Sanofi, Regeneron, IGM BIosciences, Nektar, Harpoon, Adaptive Biotechnologies, Caelum, Abbvie 	Consultancy: Sebia, Janssen, BMS, Sanofi, HopeAI, Adaptive Biotechnologies, Abbvie 	2024-09-01
Elizabeth J. Davis 	Trial funding: Incyte, Cornerstone, Cogent, Bio Atla, Actuate 	Consulting: Deciphera, Aadi, SpringWorks 	2024-11-05
Bhagirathbhai Dholaria	Research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir 	Consulting/Advisory Board: Jazz, Gamida Cell, MJH BioScience, Arivan Research, BEAM therapeutics, Janssen, Atheneum; Study steering committee: Gamida Cell 	2024-08-01
Elaine Fan 	Nothing to disclose 	Consulting: Westat 	2024-07-31
Rachel Feaster 	Nothing to disclose 	Freelance medical writer for GoodRx and Pharmacy Times. Served as faculty member for Pharmacy Times symposia. 	2024-03-13
Austin Fitts 	Nothing to disclose 	Consulting: Westat 	2024-08-07
Teja Ganta 	Nothing to disclose 	Nothing to disclose 	2024-11-08
Michael J. Glover 	Nothing to disclose 	Nothing to disclose 	2024-11-04
Gaurav Goyal 	NIH/NCI 	Consultancy: Recordati; Advisory Board: Opna Bio, Seagen, Sobi 	2024-11-22
Laura Graham 	Nothing to disclose 	Nothing to disclose 	2023-09-11
Matthew Hadfield 	Nothing to disclose 	Nothing to disclose 	2024-08-01
Talal Hilal 	NIH/NCI 	Consulting/Advisory Board: Incyte; Editorship: Springer 	2024-08-07
Sandeep K. Jain 	Nothing to disclose 	HemOnc.org internship (2023-2024) 	2024-06-13
Georgina Kennedy 	Nothing to disclose 	Nothing to disclose 	2024-11-01
Ali R. Khaki 	23andMe, Janssen, Acrivon Therapeutics 	Consulting/Advisory Board: Seagen/AstellasTravel: BCAN; SABCSHonoraria: Onclive CME 	2024-08-13
Ashwin Kishtagari 	Nothing to disclose 	Consulting/Advisory Board: Sobi (CTI biopharma), Geron, Morphosys, Rigel, Servier Pharmaceuticals, Syndax 	2025-01-02
Shalin Kothari 	Nothing to disclose 	Consulting/Advisory Board: ADC therapeutics 	2024-09-30
Amit Kulkarni 	Research Funding to Institution: Astra Zeneca 	Speaker Bureau: Regeneron; Consulting/Advisory Board: Exelixis; Stock and Other Ownership Interests: Merck, Exact Sciences, Eli Lilly, Abbvie. 	2023-08-03
Mary L. Kwok 	BeiGene 	Bristol Myers Squibb Foundation 	2024-11-01
Wayne H. Liang 	Nothing to disclose 	Consulting/Advisory Board: Westat, ChemoMap, Genoplex.ai 	2024-10-17
Maryam Lustberg 	AstraZeneca, Novartis 	Consulting/Advisory Board: Novartis, Lily, Gilead, Menarini 	2024-11-02
Mark P. Lythgoe 	Nothing to disclose 	Nothing to disclose 	2024-11-03
Emily A. Mann 	Nothing to disclose 	Nothing to disclose 	2025-01-02
Eric Marks 	Research funding: Merck 	Consulting/Advisory Board: Sermo, Medscape, Brand Institute, M3 	2023-06-28
Mary Mesnard 	Nothing to disclose 	Nothing to disclose 	2024-07-31
Sanjay R. Mohan 	Research funding: NCCN, Ichnos, Incyte, Kartos, Karyopharm, Taiho 	Nothing to disclose 	2024-12-31
Francesca Montanari 	Nothing to disclose 	Honoraria: Acrotech, BeiGene 	2024-11-02
Gayathri Nagaraj 	Nothing to disclose 	Consulting: SyndevRx, Lilly, AstraZeneca 	2024-07-16
Seema Nagpal 	Trial funding: Agios, PharmAbcine, Insightec, Berg, Inovio 	Nothing to disclose 	2024-08-05
Ryan Nguyen 	Exelixis, Iovance (research funding to institution) 	Merck, Bristol Myers Squibb, Pfizer (speaker's bureau) 	2025-01-22
David Noyd 	Nothing to disclose 	Consulting/Advisory Board: Westat 	2024-07-31
Irbaz Bin Riaz 	NIH/NCI 	Nothing to disclose 	2024-11-01
Laura Roccograndi 	Nothing to disclose 	Pharmacy Times CE 	2024-03-03
Michael K. Rooney 	Nothing to disclose 	Nothing to disclose 	2024-08-14
Samuel R. Rubinstein 	Nothing to disclose 	Consulting/Advisory Board: BMS, Johnson+Johnson, Sanofi 	2025-01-15
Martin Schoen 	St. Louis Veterans Affairs Medical Center, Congressionally Directed Medical Research Program 	Consulting/Advisory Board: Doximity, Pfizer 	2023-08-11
Tarsheen Sethi 	Nothing to disclose 	Nothing to disclose 	2024-11-01
Sanjai Sharma 	Nothing to disclose 	Nothing to disclose 	2023-09-11
Aditya Shreenivas 	Research funding to Medical College of Wisconsin from Natera. Research support for data analysis and publication, Caris to Medical College of Wisconsin 	Advisory board Taiho Oncology in Medical College of Wisconsin; Investigator Target Cancer Foundation (not for profit) 	2024-12-16
Eric K. Singhi 	Nothing to disclose 	Consulting/Advisory Board: AstraZeneca, Novocure, Amgen, Janssen, Regeneron, Bayer, BMS, BI, Eli Lilly 	2024-12-31
Benjamin F. Tillman 	Nothing to disclose 	Nothing to disclose 	2024-11-02
Emily Waite 	Nothing to disclose 	Speaker's Bureau: Servier 	2024-03-06
Nicole M. Wood 	Nothing to disclose 	Consulting/Advisory Board: Westat 	2024-07-31
Peter C. Yang 	Nothing to disclose 	Ownership: HemOnc.orgStock: Merck, Pfizer 	2025-01-31
Carolnn Yong 	Nothing to disclose 	Nothing to disclose 	2024-03-04
Travis Zack 	Nothing to disclose 	Nothing to disclose 	2023-09-05
Marjorie Zauderer 	Memorial Sloan Kettering receives research funding from the Department of Defense, the National Institutes of Health, Precog, GlaxoSmithKline, Epizyme, Polaris, Sellas Life Sciences, Bristol Myers Squibb, Millenium/Takeda, Curis, and Atara for research conducted by Dr. Zauderer.	In the last 3 years, Dr. Zauderer has received consulting fees from Curis, Ikena, Takeda, GlaxoSmithKline, Aldeyra Therapeutics, Novocure, and Atara and honoraria for CME content from PER, Medscape, Research to Practice, Medical Learning Institute and OncLive. Dr. Zauderer serves as Chair of the Board of Directors of the Mesothelioma Applied Research Foundation, uncompensated.	2024-08-08
Leyre Zubiri 	Nothing to disclose 	Nothing to disclose 	2024-12-16
Category:Null pages